Benzinga | Apr 8, 2021 08:29AM EDT

BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study

* BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental oxygen without mechanical ventilation.

* The study did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen compared to placebo.

* There were no new or additional safety signals for zanubrutinib identified in the trial.

* BeiGene expects to submit these data for scientific presentation or publication in the future.

* Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase (BTK).

* Price Action: BGNE shares closed 2.3% lower at $321.60 on Wednesday.